Meta-analysis of the efficacy of different therapy regimens in eradicating Helicobacter pylori;Metaanalyse zur feststellung der keimeradizierenden potenz verschiedener therapieschemata bei Helicobacter-pylori-infektion

Wiener Medizinische Wochenschrift

Volumn 148, Issue 20, 1998, Pages 464-468

  Dobrucali, A ^a   Canbakan, B ^a,b   Canbakan, M ^a   Bagatur, N ^a   Uzunismail, H ^a   Eralp, Y ^a   Akun E ^a   Goksel S ^a   Yurdakul, I ^a   Oktay, E ^a  

^a Aus der Abt F Gastroenterologie   (Turkey)

^b Ölçek Sokak   (Turkey)

Author keywords

Cost analysis; Eradication rates; Helicobacter pylori therapy; Meta analysis; Therapy side effects

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; ANTIULCER AGENT; BISMUTH; CLARITHROMYCIN; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; SUCRALFATE; TETRACYCLINE;

ADULT; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DUODENUM ULCER; FEMALE; GASTRITIS; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; STOMACH ULCER; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; LYMPHOMA, B-CELL; MALE; PRECANCEROUS CONDITIONS; STOMACH NEOPLASMS;

EID: 0032435803     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Axon ATR: The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994;29 (suppl 201): 16-23.
2. Black M: Hepatotoxic and hepatoprotecive potential of histamine (H2) receptor antagonists. Am J Med 1987;83 (suppl 6a): 68.
3. Caspary WF, Rösch W: Diagnostik und Therapie der Helicobacter-pylori-Infektion bei Erwachsenen. Dtsch Med Wschr 1996;121:1375-1378.
4. Cavanaugh J, Winters E, Cohen A, et al: Lack of effect of Lansoprazole on steady state warfarin metabolism. Gastroenterology 100 (suppl): A40 (abstr).
5. De Boer WA, Tygat GNJ: The best therapy for Helicobacter pylori infection: Should efficacy or side effect profile determine our choice? Scand J Gastroenterol 1995;30:401-407.
6. De Boer WA, Driessen WMM, Potters HVPJ, Tygat GNJ: Randomized study comparing 1 with 2 weeks quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994;89:1993-1997.
7. Goh KL, Navaratnam P, Peh SC, et al: Helicobacter pylori eradication with shortterm therapy leads to duodenal ulcer healing without the need for continued acid suppression therapy. Eur J Gastroenterol Hepatol 1996;8:421-423.
8. Gorbach SL: Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990;99:863-875.
9. Graham DY: Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med 1993;328:349.
10. Holtmann G, Layer P, Goebell H: Sind Protonenpumpeninhibitoren den H2-Rezeptorenantagonisten im Rahmen der H.-pylori-Eradikationstherapie überlegen? Metaanalyse vorliegender Parallelgruppenvergleiche. Z Gastroenterol 1996;34:267-272.
11. Koch KM, Davis IM, Gooding AE, Yin Y: Pharmacokinetics of bismuth and ranitidine following single doses of ranitidlne bismuth citrate. Br J Clin Pharmacol 1996;42:201-205.
12. Labenz J, Börsh G: Klinik und Diagnostik der Helicobacter-pylori-Infektion. Dtsch med Wschr 1994;119:633-636.
13. Labenz J, Tillenburg B, Peitz U, Köhl H, Becker T, Stolte M, Börsch G: Ulcusheilung durch Helicobacter-pylori, Eradikation: Genügt eine Woche Therapie? Dtsch med Wschr 1996;121:3-8.
14. Lambert JR, Lin SK, Aranda-Michel J: Helicobacter pylori. Scand J Gastroenterol 1995;30 (suppl 208): 33-46.
15. Lewis JH: GI drug column: Hepatic effects of drugs used in treatment of peptic ulcer disease. Am J Gastroenterol 1987;82:987.
16. Marchi E: Comparative efficacy and tolerability of clarithromycin and amoxycillin in the treatment of out-patients with acute maxillary sinusitis. Curr Med Res Opin 1990;12:19-24.
17. Markham A, McTavish D: Clarithromycin and Omeprazole. Drugs 1996;51:161-168.
18. McCarthy D: Treatment and prevention of nonsteroidal anti-inflammatory drug-associated ulceration. Ann Intern Med 1991; 114:307.
19. Megraud F: H, pylori resistance to antibiotics. In Hunt RH, Tygat GNJ (eds): Helicobacter pylori. Basic Mechanisms to clinical Cure. Dordrecht, Kluwer Academic Publishers, 1994, pp 570-583.
20. Olbe L, Hamlet A, Dalenbaeck J, et al: Mechanism by which Helicobacter pylori infection of the antrum contributes to the development of duodenal ulcer. Gastroenterology 1996;110:1386-1394.
21. Penston JG: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994;8: 369-389.
22. Pipkin GA, Mills JG, Kler L, Dixon JS, Wood JR: The safety of ranitidine bismuth citrate in controlled clinical studies. Pharmacoepidemiol Drug Safety 1996;5:399-407.
23. Pratzer U, Holtermüller KH: Omeprazol. Dtsch med Wschr 1993;118:230-239.
24. Sherwood L Gorbach: Bismuth therapy in gastrointestinal diseases. Gastroenterology 1990;99:863-875.
25. Spencer MC, Foulds D: Focus on Lansoprazole. Drugs 1994;48:404-430.
26. Tillenburg B, Labenz J, Siehoff S, et al: The situation of primary resistance of Helicobacter pylori to commonly used antibiotics in Germany. Am J Gastroenterol 1995;90:1594.
27. Tygat GNJ: Review article. Treatments that impact favourable upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994;8:359-368.
28. Tygat GNJ, Lee A, Graham DY, Dixon MF, Rokkas T: The role of infectious agents in peptic ulcer disease. Gastroenterol Internal 1993;5:76.
29. Unge P: Review of Helicobacter pylori eradication regimens. Scand J Gastroenterol 1996;31 (suppl 215): 74-81.
30. Yeomans ND: Omeprazole: Short - and long-term safety. Adverse Drug React Toxicol Rev 1994;13:145.